AnaptysBio Inc (NASDAQ:ANAB) was the recipient of a significant increase in short interest during the month of December. As of December 29th, there was short interest totalling 1,387,012 shares, an increase of 40.3% from the December 15th total of 988,390 shares. Currently, 9.8% of the shares of the company are short sold. Based on an average daily volume of 280,607 shares, the short-interest ratio is currently 4.9 days.
AnaptysBio (NASDAQ:ANAB) opened at $112.40 on Friday. AnaptysBio has a fifty-two week low of $15.17 and a fifty-two week high of $114.47. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. analysts forecast that AnaptysBio will post -1.72 EPS for the current year.
Several equities analysts have commented on ANAB shares. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price objective on the stock in a report on Friday, November 10th. SunTrust Banks started coverage on shares of AnaptysBio in a report on Wednesday, November 15th. They issued a “buy” rating and a $115.00 price objective on the stock. Royal Bank of Canada upped their price objective on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Credit Suisse Group upped their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Finally, Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. AnaptysBio currently has an average rating of “Buy” and a consensus price target of $88.00.
Hedge funds have recently added to or reduced their stakes in the stock. Evercore Wealth Management LLC acquired a new position in shares of AnaptysBio in the third quarter valued at about $100,000. Legal & General Group Plc grew its stake in shares of AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 1,951 shares in the last quarter. DAFNA Capital Management LLC grew its stake in shares of AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 1,000 shares in the last quarter. New York State Common Retirement Fund acquired a new position in shares of AnaptysBio in the second quarter valued at about $168,000. Finally, Nationwide Fund Advisors grew its stake in shares of AnaptysBio by 89.5% in the third quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,776 shares in the last quarter. Institutional investors and hedge funds own 75.48% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2018/01/14/anaptysbio-inc-anab-sees-significant-increase-in-short-interest.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.